Ardent Health (ARDT) Stock Overview
Owns and operates a network of hospitals and clinics that provides healthcare services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ARDT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ardent Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.40 |
| 52 Week High | US$15.48 |
| 52 Week Low | US$7.71 |
| Beta | 0 |
| 1 Month Change | 1.84% |
| 3 Month Change | 7.06% |
| 1 Year Change | -28.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.47% |
Recent News & Updates
Recent updates
Narrative Update • Jun 15
ARDT: Volume Softness And New Leadership Will Shape Balanced Risk Profile
Analysts nudged their price target on Ardent Health to $12. This reflects mixed recent commentary that includes concerns around softer Q2 volumes and a more challenging macro backdrop, alongside a modest upward revision from other firms.
Narrative Update • Jun 01
ARDT: Stabilizing Volumes And Expense Control Will Support Future Repricing
Ardent Health's updated analyst price target edges higher to $12.50, reflecting slightly adjusted assumptions around discount rate, modest revenue growth expectations, and improved profit margin forecasts, as analysts weigh recent target changes from firms citing stabilized operations, solid volumes, and expense control against what they view as an overly harsh valuation. Analyst Commentary Recent research updates on Ardent Health show a mix of optimism on operations and caution on valuation and execution, which feeds into the updated US$12.50 price target.
Narrative Update • May 15
ARDT: Expense Discipline And Stabilizing Operations Will Support Future Upside Potential
Ardent Health's updated analyst fair value estimate has shifted from $17.00 to $14.00, as analysts weigh recent price target moves, including cuts from Guggenheim, UBS, and Leerink that reflect more measured growth assumptions, along with acknowledgment of stabilized operations and solid expense control. Analyst Commentary Recent research on Ardent Health points to a mix of caution and optimism, with several firms revising price targets while acknowledging areas of operational strength.Analysis Article • May 08
Results: Ardent Health, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Ardent Health, Inc. ( NYSE:ARDT ) came out with its first-quarter results last week, and we wanted to see how the...Narrative Update • Apr 28
ARDT: Stabilizing Volumes And Expense Discipline Will Support Share Repricing
Ardent Health's updated analyst price target reflects a modest reset, with cuts such as Guggenheim's $2 reduction and recent moves to $15 at Leerink and $13 at UBS, as analysts balance more cautious valuation views with observations of stabilizing operations and expense discipline. Analyst Commentary Bullish Takeaways Bullish analysts highlight Q4 results as an improvement versus the prior quarter, which they see as evidence that operations are becoming more consistent and execution is tightening.Narrative Update • Apr 14
ARDT: Q4 Volume Strength And Cost Controls Will Support Share Repricing
Ardent Health's analyst price target has been trimmed by about $0.30 as analysts factor in slightly lower fair value and P/E assumptions, while still citing solid volumes, improving payer denial trends, and what they view as an overly harsh current valuation. Analyst Commentary Recent Street research on Ardent Health points to a mixed but generally constructive tone, with price targets easing while core operating trends are described as improving and the current share price framed as undemanding by some analysts.Narrative Update • Mar 31
ARDT: Q4 Stabilization And Cost Controls Are Expected To Support Repricing
Ardent Health's analyst price target has been nudged lower by about $0.33, reflecting a slightly reduced fair value estimate as analysts factor in updated assumptions on growth and discount rates, while still pointing to Q4 stabilization and a valuation they view as overly harsh. Analyst Commentary Recent Street research reflects a mix of optimism around Ardent Health's operating trends and a more cautious stance on valuation, with both sets of analysts trimming their price targets while maintaining positive ratings.Narrative Update • Mar 17
ARDT: Future Earnings Guidance And Legal Overhang Will Shape Risk Balance
Analysts have trimmed their price target on Ardent Health to $9.38 from $13.06 as they factor in more conservative revenue growth and profit margin assumptions, partly offset by a higher future P/E multiple. They still view the recent $15 and $13 Street targets as reflecting what they see as overly harsh current pricing.Narrative Update • Mar 03
ARDT: Virtual Care Expansion And Cost Controls Are Expected To Support Recovery
Analysts have nudged their Ardent Health price target slightly higher to $13.07, reflecting modest tweaks to their discount rate and long term P/E assumptions while keeping fair value estimates essentially unchanged. What's in the News Ardent Health entered a partnership with hellocare.ai to serve as its enterprise platform for AI assisted virtual physician, virtual nursing, virtual patient observation and patient safety tools, with deployment planned across more than 2,000 patient rooms and a wide range of inpatient settings.Narrative Update • Feb 16
ARDT: Strong Demand And Cost Mitigation Efforts Are Expected To Support Recovery
Analysts have reduced their price target on Ardent Health to $13 from $20, citing recent pressure from higher professional fees and payer denials. They also note solid demand trends that they believe could help the company manage these costs over time.Narrative Update • Feb 02
ARDT: Margin Initiatives And Strong Demand Trends Are Expected To Support Recovery
Ardent Health's updated analyst price target narrows slightly to about $13.07 from $13.23, as analysts factor in higher discount rates and cost pressures from professional fees and payer denials. At the same time, they acknowledge steady revenue growth assumptions and a modestly lower future P/E outlook.Narrative Update • Jan 19
ARDT: Margin Actions And Strong Demand Trends Should Support Future Recovery
Ardent Health's analyst price target has been reduced by about $0.73 to roughly $13.23, as analysts factor in weaker margins tied to higher professional fees and payer denials. They also acknowledge ongoing efforts to manage these pressures and support future performance.Narrative Update • Jan 05
ARDT: Margin Initiatives And Strong Demand Trends Will Support Future Recovery
Ardent Health's analyst price targets have generally moved lower, with cuts such as Mizuho's shift to $13 from $20 and several firms trimming their views after a disappointing quarter, as analysts balance concerns around elevated professional fees and payer denials with expectations that demand trends and margin initiatives could support future improvement in sales growth and profitability. Analyst Commentary Recent research views on Ardent Health reflect a split picture, with some firms lowering ratings or stepping to the sidelines and others still seeing room for the shares to work over time.Narrative Update • Dec 14
ARDT: Margin Initiatives And Demand Strength Will Drive Future Share Recovery
Ardent Health's updated fair value estimate has been reduced from $23.00 to $17.00 per share as analysts trim price targets in response to weaker margins from elevated professional fees and payer denials, even as they highlight resilient demand and ongoing cost mitigation efforts. Analyst Commentary Bullish analysts acknowledge the near term margin setbacks but emphasize that Ardent Health's demand backdrop remains constructive, with volume trends viewed as sufficient to support revenue growth even as the company works through higher professional fees and payer denials.Narrative Update • Nov 29
ARDT: Margin Pressures Will Ease As Cost Programs Improve Efficiency
Ardent Health's analyst price target has been lowered from approximately $15.62 to $13.96. Analysts cite persistent margin pressures, elevated professional fees, and ongoing payer denials as contributing factors, despite continued strength in demand and sales growth potential.Narrative Update • Nov 15
ARDT: Margin Initiatives Will Drive Share Recovery Despite Persistent Cost Headwinds
Ardent Health's fair value estimate has been revised down from $19.08 to $15.62. Analysts cite ongoing cost pressures, weaker guidance, and concerns over revenue growth as key factors behind the lower price targets.Narrative Update • Sep 11
Expanding US Outpatient Services Will Meet Evolving Healthcare Demands
With both Ardent Health’s future P/E and consensus revenue growth forecasts holding steady, analysts have made only a marginal downward revision in their fair value estimate, lowering the price target from $19.27 to $19.08. What's in the News Ardent Health reaffirmed full-year 2025 earnings guidance, projecting total revenue between $6.2 billion and $6.45 billion and diluted EPS in the range of $1.73 to $2.01.New Narrative • Jul 20
Expanding Urban And Suburban Outpatient Access Will Fuel Future Demand
Expansion in outpatient care and partnerships, including acquisitions and joint ventures, is strengthening market position and diversifying revenue streams.Analysis Article • Jul 18
Is Ardent Health (NYSE:ARDT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jul 17
Ardent Health: The Best Prospect In An Industry That's Facing Challenges
Summary Ardent Health faces significant legislative risks, due to Medicaid and Medicare cuts, causing uncertainty and a recent downgrade, but much of this is priced in. Despite headwinds, Ardent Health demonstrates strong revenue and profitability growth, low leverage, and trades at compellingly cheap valuations, versus peers. Management projects continued growth for 2025, with revenue and EBITDA expected to rise, supported by higher-margin service expansions and acquisitions. Given its financial strength and discounted valuation, I assign ARDT stock a speculative 'buy' rating, believing it can weather the policy-driven storm. Read the full article on Seeking AlphaAnalysis Article • Apr 16
Estimating The Fair Value Of Ardent Health Partners, Inc. (NYSE:ARDT)
Key Insights The projected fair value for Ardent Health Partners is US$11.90 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Feb 22
Is Ardent Health Partners (NYSE:ARDT) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| ARDT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.5% | 0.07% | -2.3% |
| 1Y | -28.4% | 19.3% | 21.2% |
Return vs Industry: ARDT underperformed the US Healthcare industry which returned 19.3% over the past year.
Return vs Market: ARDT underperformed the US Market which returned 21.2% over the past year.
Price Volatility
| ARDT volatility | |
|---|---|
| ARDT Average Weekly Movement | 7.9% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARDT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARDT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 22,350 | Dave Caspers | www.ardenthealth.com |
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers.
Ardent Health, Inc. Fundamentals Summary
| ARDT fundamental statistics | |
|---|---|
| Market cap | US$1.32b |
| Earnings (TTM) | US$134.28m |
| Revenue (TTM) | US$6.43b |
10.0x
P/E Ratio0.2x
P/S RatioIs ARDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDT income statement (TTM) | |
|---|---|
| Revenue | US$6.43b |
| Cost of Revenue | US$2.66b |
| Gross Profit | US$3.77b |
| Other Expenses | US$3.63b |
| Earnings | US$134.28m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 58.60% |
| Net Profit Margin | 2.09% |
| Debt/Equity Ratio | 63.1% |
How did ARDT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 22:10 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ardent Health, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Fischbeck | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Scott Fidel | Goldman Sachs |